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AbstrACt
Objectives Patients with non-traumatic lower extremity 
amputation are characterised by high age, multi-morbidity 
and polypharmacy and long-term complications of 
atherosclerosis and diabetes. To ensure early identification 
of patients at risk of amputation, we need to gain 
knowledge about the progression of diseases related to 
lower extremity amputations during the years preceding 
the amputation.
Design A retrospective population-based national registry 
study.
setting The study includes data on demographics, 
diagnoses, surgery, medications and healthcare services 
from five national registries. Data were retrieved from 
14 years before until 1 year after the amputation. 
Descriptive statistics were used to describe the 
progression of diseases and use of medication and 
healthcare services.
Participants An unselected cohort of patients (≥50 years; 
n=2883) subjected to a primary non-traumatic lower 
extremity amputation in 2010 or 2011 in Denmark.
results The prevalence of atherosclerosis, hypertension 
and diabetes was 70%, 53% and 49%, respectively. 
Among patients with atherosclerosis, 42% had not 
received cholesterol-lowering treatment even though 87% 
had visited their general practitioner within the last year 
prior to amputation. Further, 16% were diagnosed with 
diabetes at the time of the amputation. The prevalence 
of cardiovascular diseases increased from 22% to 70%, 
atherosclerosis from 5% to 53% and diabetes from 17% 
to 35% over the 14 years preceding major amputation. 
Of all patients, 64% had been in contact with the hospital 
or outpatient clinics within the last 3 years, and 29% 
received a prescription of opioids 3 years prior to the 
amputation.
Conclusion Among patients with non-traumatic lower 
extremity amputation, one-third live with undiagnosed 
and untreated atherosclerosis and one-sixth suffer from 
undiagnosed diabetes despite continuous contacts 
to general practitioner and the hospital. This study 
emphasises a need for enhanced focus, among both 
hospital clinicians and general practitioners, on the early 
identification of atherosclerosis and diabetes.
IntrODuCtIOn
Lower extremity amputation (LEA) is a severe 
event associated with loss of mobility, pain, 
decreased quality of life, major disfigure-
ment and increased risk of reamputation and 
hospitalisation.1–3 Even though the world-
wide incidence of LEA has declined over the 
last 2 decades, significant variations persist: 
from 5.8 to 31 per 105 individuals in different 
populations.4 The reported 1-year mortality 
rate was 12%–58%,5–8 with the highest 
mortality rate (45%–58%) associated with 
above-the-knee amputations (AKAs).9 10 Age 
and the severity of comorbidities are the most 
prominent prognostic factors for mortality 
after LEA.6 7
The most prevalent comorbidities in 
patients with LEA are atherosclerosis primary 
as periphery vascular disease (PAD) and 
diabetes.4 11–13 Studies have reported the 
strengths and limitations of the study
 ► The strengths of this national registry study were the 
inclusion of data describing diagnoses and use of 
medication and healthcare services during the last 
14 years preceding non-traumatic lower extremity 
amputation performed in Denmark.
 ► The use of national registry which enables the 
inclusion of all patients who had undergone a lower 
limb amputation in Denmark and thereby limits the 
risk of selection bias.
 ► The main limitation was the lack of a control group. 
An age-matched, sex-matched and geographically 
matched control group would have allowed 
differentiation between disease progression due 
to ageing and disease progression leading to 
amputation. An inherent limitation was that the data 
did not allow an estimation of patient compliance 
with the prescribed medication.
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prevalence of diabetes to be between 52% and 64%,3 5 14 
and approximately 80% of the patients with LEA are either 
diagnosed with diabetes or PAD.12 In a cohort of patients 
with diabetes, 18% had a cardiovascular disease (CVD) 
with PAD being most prevalent.15 Among patients diag-
nosed with both diabetes and PAD, the risk of amputation 
is 1.5 times higher than in patients diagnosed with PAD 
alone and five times higher than in patients only diag-
nosed with diabetes.13 The global prevalence of diabetes 
and PAD among patients with LEA varies among popula-
tions due to ethnicity and socioeconomic.4 16 Currently, 
the global prevalence of diabetes is estimated to be 9% 
of which 90% is characterised as type 2 diabetes17 and is 
expected to continue to increase over the next 20 years 
to 10%. During the last decade, the global prevalence 
of PAD has increased by 23%, with the highest increase 
among low-income countries.18 The risk factors for PAD 
are age, smoking, diabetes, hypertension, dyslipidaemia 
and obesity.19 The National Institute For Health and 
Clinical Excellence guidelines for lower limb peripheral 
arterial disease state that there is substantial evidence 
establishing benefits for lowering cholesterol drugs for 
patients with PAD, and the use of limb-saving procedure 
is also recommended.20 The benefits of cholesterol-low-
ering drugs have shown a significant reduction in the risk 
of major amputation.21 22
To our knowledge, only a few studies have previ-
ously investigated the progression of diseases and use 
of healthcare services before amputation using histor-
ical longitudinal data. One case-control study including 
data collected 7 years before amputation and recom-
mended early referral to a medical specialist to prevent 
LEA among patients with diabetes,23 although a popula-
tion-based study found that repeated visit to the hospital 
did not lower the risk of amputation among patients 
with diabetes and PAD.24 Other studies have also shown 
delayed referral to revascularisation to prevent loss of 
extremity and inadequate treatment of cholesterol-low-
ering drug.25 26
Nevertheless, the risk of amputation remains high, and 
some patients remain undiagnosed until it is too late to 
prevent LEA.27 The first step to improving the early iden-
tification is to acquire more knowledge of the characteris-
tics of patients, variation and progression of diseases and 
use of healthcare services prior to amputations. The aim 
of this study was to explore the progression of LEA-re-
lated diseases. We examined the use of medication and 
the number of contacts with healthcare services during 
the 14 years leading up to LEA, among all Danish patients 
that underwent LEAs in 2010 or 2011. Finally, we studied 
the associations between LEA-related diseases and the 
1-year prognosis after the LEA.
MethODs
setting
The Danish healthcare system is tax funded and offers 
free and equal access to medical care. All citizens have 
a general practitioner (GP) who provides referrals to 
specialists and hospital treatments. The GPs are respon-
sible for their patients’ medical treatment. Prescribed 
medications and other healthcare services, such as a 
physiotherapy, among others, are partly tax funded, with 
a differential out-of-pocket fee.
study design and data sources
We included data from the following five national 
registries: The National Patient Registry (NPR), which 
contains information on hospitalisations, including visits 
to outpatient clinics and emergency rooms,28 surgical 
procedures, coded according to the Nordic Classification 
of Surgical Procedures, and diagnoses coded according 
to the International Classification of Diseases (ICD-10); 
the National Prescription Registry, which contains infor-
mation on prescribed medications picked up at the phar-
macy,29 where the data are coded according to the global 
Anatomical Therapeutic Chemical classification system; 
the Danish National Health Service Registry for Primary 
Care, which contains information on all contacts with 
GPs, including out-of–hours care from GPs and prac-
tising medical specialists;4 30the Danish Civil Registration 
System, which contains information on gender, date of 
birth, vital status, spouses and residents;31 and the Attain-
ment Registry, which contains data on education level. 
All Danish citizens are registered with a unique personal 
identification number (Central Personal Registration 
CPR number), which allows linkage with all national regis-
tries at an individual level. Statistics Denmark provided 
the data (http://www. danmarksstatistik. dk/ en).
study cohort
We included patients with at least one of the following 
surgical procedures, performed between 1 January 2010 
and 31 December 2011: hip exarticulation or trans-fem-
oral amputation (ie, AKA), knee disarticulation or trans-
tibial amputation (ie, below-the-knee amputation (BKA)), 
foot amputation or toe amputation. See online supple-
mentary material 1 for detailed information. To eliminate 
trauma-related amputations, we excluded patients with a 
trauma diagnosis recorded at any time prior to the ampu-
tation. We also excluded foreign patients without a CPR 
number or below 18 years of age. To ensure homogeneity 
within the groups, we defined an index amputation as the 
first surgical amputation performed as an AKA, BKA, foot 
or toe amputation in 2010 and 2011.
Categorisation of amputation procedures
For patients who received more than one amputation 
procedure on the same day, the most severe (proximal) 
procedure was identified for analysis. The severity of 
different types of amputations (based on surgical codes) 
was ranked from the most severe procedure as hip exar-
ticulation and transfemoral amputation to the least 
severe as a toe amputation procedure. A detailed descrip-
tion is present in online supplementary material 1. When 
patients had both a left-side and right-side amputation 
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code on the same day, the procedure was categorised as 
a bilateral amputation. AKA and BKA were classified as 
major amputations, and foot or toe amputations were 
classified as minor amputations.
Demographics, comorbidities, medications and contacts with 
healthcare services
For each patient, we retrieved cumulative registry infor-
mation on the education level, living conditions, socio-
economic status, place of residence, diagnoses, prescribed 
medications, contacts with healthcare services, reampu-
tations and death, which had been recorded between 1 
January 1997 and 31 December 2012. The Elixhauser 
Comorbidity Index was used to identify the progres-
sion of comorbidities over the 14 years prior to amputa-
tion. The Index includes 31 predefined comorbidities; 
however, in this study, we combined the predefined codes 
for uncomplicated and complicated diabetes and hyper-
tension.32 The Elixhauser Comorbidity Index was supple-
mented with ICD-10 codes for atherosclerosis, including 
atherosclerosis in the lower extremities, diabetic neurop-
athy, retinopathy, nephropathy foot ulcer, other ulcers 
(not related to diabetes), stroke, emboli, bone cancer 
and arthrosis; see online supplementary material 1. The 
severity of the comorbidity identified at the time of the 
index amputation was evaluated with the Charlson Comor-
bidity Index.33 We divided the patients into three groups, 
according to the Charlson Comorbidity Index: 0–1, 2 and 
3+, where a higher score predicted an increased risk of 
mortality. The prescribed medications were defined as 
medications that were picked up from the pharmacy at 
least once each year. The prescribed medications were 
grouped according to Anatomical Therapeutic Chemical 
(ACT) codes. The coding and the classifications of drugs 
were defined by the authors and validated by consensus 
agreement among three pharmacists who did not partic-
ipate in the study; see online supplementary material 1.
The NPR registry contains only information on diag-
noses recorded during hospitalisation, and not by GPs. 
Therefore, central diseases were defined by combining 
the prevalence of the medication (ACT codes) collected 
from the pharmacy with the registered diagnosis (ICD-10 
codes) from hospitals: diabetescomb, atherosclerosiscomb, 
cardiovascular diseasescomb and hypertensioncomb (see 
online supplementary material 1). A visit to a GP was 
defined as a show-up at the GP clinic, and visits to outpa-
tient clinics included only clinics at the hospitals, while a 
visit to a medical specialist only includes private clinics.
ethical approval
This register-based study included only anonymous data 
from national registries and had no patient contact. The 
scientific board of Statistics Denmark and ‘Statens Serum 
Institut’ approved the study (project no 704122).
Statistics
Descriptive data, comorbidities and the use of medica-
tion for each of the amputation groups were expressed 
as frequencies with percentages, for categorical data, 
or as median and intraquartile range (IQR=25th to 
75th percentile) for continuous data. A comparison 
between major and minor amputations was made with 
a χ2 test, for categorical data, and a Kruskal-Wallis test 
for continuous data. Diagnoses and relevant medica-
tions were compared between amputation types and 
atherosclerosis, diabetes, hypertension and between 
CVD, diabetes and patients without. The prevalence 
of diagnoses and use of medications over time are 
depicted as graphs of the proportions of patients with 
a given disease and the proportion that used a given 
medication, respectively. The difference in prevalence 
over time is expressed as per cent point (pp). The 
outcome following the amputations, are presented as 
cumulative incidence plots where death was modelled 
as a competing event. The data analysis was performed 
with SAS 9.4, and the cumulative incidence plots were 
constructed with R 3.2.2. Graphs of the progression 
over time were created with GraphPad Prism 6.07, and 
the flowchart was created in PowerPoint 2010. p Values 
less than 5% were considered significant.
results
A total of 3375 patients underwent an LEA in Denmark 
during 2010 and 2011. Of these, 4% required LEAs due 
to trauma and were excluded from the cohort (figure 1). 
Additionally, 352 patients (11%) were excluded, due to 
a previous amputation on the same or opposite leg, at 
the same or a higher level, leaving 2883 patients who 
fulfilled the criteria for undergoing an index amputa-
tion during 2010 and 2011. Major amputations were 
performed in 1782 patients (62%), and minor ampu-
tations were performed in 1101 patients (38%). Patient 
characteristics are presented in table 1. Among patients 
with major amputations, 1562 (88%) had not received 
previous amputations. Among the 266 patients with 
previous amputations (on a lower level), 101 patients 
(38%) were bilaterally amputated.
Comorbidities and medical treatment in the year of 
amputation
Patient diagnoses and current medications that were 
recorded at the time of the index amputation are 
presented in tables 2 and 3. Both diabetes and athero-
sclerosis were diagnosed in 32% of patients (577/1782) 
with major amputations and 35% of patients (382/1101) 
with minor amputations. A subgroup analysis of charac-
teristics, comorbidities and medical treatment among 
patients diagnosed with either CVD including arterio-
sclerosis, diabetes or neither is presented in table 4. A 
total of 2350 (82%) patients were diagnosed with CVD 
of which 1185 had CVD without diabetes and 1451 
patients were diagnosed with diabetes of which 286 were 
not diagnosed with CVD. Furthermore, among patients 
diagnosed with atherosclerosis, 42% (851/2017) had 
not received cholesterol-lowering drugs at the time of 
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amputation. The absence of cholesterol-lowering treat-
ment was observed significantly more among patients 
with major amputations than among those with minor 
amputations (46% (650/1428) vs 34% (201/589); 
p<000.1). Among patients diagnosed with CVDs and 
patients diagnosed with diabetes, 46% (543/1185) and 
65% (940/1451) received cholesterol-lowering before 
the amputation; see table 4. Among patients diag-
nosed with diabetes, 225 patients (16%) did not at any 
time receive insulin or blood glucose-lowering drugs 
preceding the amputation. The absence of antidiabetic 
treatment prior to the amputation was observed signifi-
cantly more often among patients with major ampu-
tations than among patients with minor amputations 
(19% (134/697) vs 13% (91/710), p<0.001).
Disease progression and medications during the 14 years 
prior to amputation
Figure 2 shows the gradual increases in the proportion 
of patients with the most common diagnoses (athero-
sclerosis, diabetes and hypertension) recorded during 
hospitalisations and the medications used (including 
antithrombotic agents, cholesterol-lowering treatments, 
antidiabetic drugs and antihypertensive therapies) 
during the 14 years prior to the amputation. Among 
patients undergoing major amputations, the prevalence 
of atherosclerosis increased from 2% to 20% over the 
first 13 years, and a 58 pp increase was observed during 
the last year preceding the amputation. During the 14 
years, the use of cholesterol-lowering drugs increased 
from 3% to 50%. There was a 28 pp difference between 
patients diagnosed with atherosclerosis who received 
cholesterol-lowering treatment and not prior to the 
amputation. Furthermore, the use of antithrombotic 
drugs increased from 15% to 65% during the first 13 
years, and the use further increased by 6 per cent point 
in the last year (figure 2a). Among patients with minor 
amputations, the prevalence of diabetes increased from 
8% to 40%, and antidiabetic treatments increased from 
29% to 55%. During the last year, the prevalence of 
diabetes increased by 21 per cent point, and the gap 
between treatment and diagnosis was only 3 per cent 
point prior to minor amputation (figure 2b). Antihyper-
tensive treatments increased from 23% to 60% during 
the first 13 years and then dropped slightly, by 4 per 
cent point, in the last year prior to a major amputation. 
Similarly, antihypertensive treatments increased from 
20% to 64% over the 14 years prior to minor amputa-
tions (figure 2c).
The estimated disease progressions, calculated as the 
combination of the diagnosis prevalence and the medica-
tion prevalence, are presented in figure 3. The progres-
sion of diseases prior to a major amputation increased 
as follows: atherosclerosiscomb increased from 5% to 53% 
during the 14 years, with a 16 per cent point increase in 
the last 5 years preceding amputation; hypertensioncomb 
increased from 23% to 63%; cardiovascular diseasescomb 
increased from 22% to 70%; and diabetescomb increased 
from 17% to 35%. The use of opioids increased from 10% 
to 45%, with an 18 per cent point increase the last 5 years 
prior to amputation. Further, 32% received prescribed 
opioids 3 years prior to major amputation (figure 3a). 
Among patients with minor amputations, the prevalence 
Figure 1 Flowchart shows study selection of patients with lower extremity amputations between 1 January 2010 and 31 
December 2011 in Denmark. Legends:1 1excluded due to previous amputation define as amputation on the same level or 
bilateral amputation on a higher level than the index amputation in 2010–2011; 2include hip exarticulation; 3include knee 
disarticulation.
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of atherosclerosiscomb increased from 3% to 51% during 
the 14 years, cardiovascular diseasescomb increased from 
16% to 63%, hypertensioncomb increased from 20% to 
66% and diabetes increased from 29% to 57%. The use 
of opioids increased from 9% to 34%, with a 12 per cent 
point increase in the last 5 years (figure 3b). In total, 29% 
received opioids 3 years before the amputation.
Contacts made to hospitals and GPs during the 14 years prior 
to amputation
Patients’ visits to the healthcare system (hospitals, outpa-
tient clinics and GPs) during the 14 years prior to amputa-
tion are presented in figure 3. A total of 98% of the patients 
contacted healthcare services at least once during the 
last year prior to amputation. The proportion of patients 
Table 1 Characteristics of patients with lower extremity amputations in 2010–2011 in Denmark
Major amputation Minor amputation
Total
n (%)
Above knee
n (%)
Below knee
n (%) n (%)
n 2883 1024 758 1101
Gender
  Male 1811 (63) 544 (53) 489 (65) 778 (71)
Age
  Men, median (IQR) 69 (61; 79) 74 (66; 82) 70 (60; 78) 66 (58; 76)
  Women, median (IQR) 78 (68; 86) 81 (72; 87) 78 (68; 85) 72 (63; 82)
Social status*
  Married† 1165 (40) 378 (37) 307 (41) 480 (44)
  Divorced 937 (32) 293 (29) 247 (33) 397 (36)
  Widow 767 (27) 352 (34) 200 (26) 217 (20)
Economic status
  Working 257 (9) 24 (2) 62 (8) 171 (16)
  Retired 2055 (71) 845 (83) 534 (71) 676 (61)
  Social welfare 571 (20) 155 (15) 162 (21) 254 (23)
Living arrangement
  Living alone 1514 (53) 595 (58) 402 (53) 517 (47)
  Living in rural areas 1705 (59) 634 (62) 431 (57) 640 (58)
Education
  <9 year of school 2549 (88) 896 (88) 662 (87) 991 (90)
Charlson Index
  0–1 546 (19) 196 (19) 133 (17) 217 (20)
  2 456 (16) 217 (21) 105 (14) 134 (12)
  3 1881 (65) 611 (60) 520 (69) 750 (68)
Multi-morbidities and polypharmacy
  Comorbidities‡, median (IQR) 7 (5; 9) 6 (5; 9) 7 (5; 10) 7 (4; 9)
  Drugs§, median (IQR) 7 (5; 9) 7 (5; 9) 7 (5; 9) 6 (4; 8)
Peripheral vascular procedure
  Angioplasty 89 (3) 7 (1) 4 (1) 78 (7)
  Bypass graft 97 (3) 5 (0; 5) 4 (1) 88 (8)
Surgery history
  Previous amputation 266 (9) 113 (11) 107 (14) 46 (4)
  <3 amputations 203 (7) 84 (8) 76 (14) 43 (4)
  ≥3 amputations 63 (2) 29 (3) 31 (4) 3 (−)
Values represent the number of patients (%), unless indicated otherwise.
*Missing n=12.
†Married or residing with a partner.
‡All ICD-10 diagnoses.
§ACT codes for main groups.
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contacting their GPs increased from 85% to 97%, and the 
mean number of visits to GPs per year increased from 4.5 
to 7.7 visits. The proportion of patients attending outpa-
tient clinics increased from 25% to 76%, and the mean 
visits to outpatient clinics per year increased from 0.4 to 
3.2 visits. During the last year prior to amputation, 2% 
of the patients had no contact with GPs or hospitals, 1% 
had only contacted hospitals and 18% had only contacted 
GPs.
Among 851 patients diagnosed with arteriosclerosis 
without receiving cholesterol-lowering drugs at any time 
prior to the amputation, 87% had visited their GP, 29% 
had called out-of-hours care, 47% had been hospitalised, 
70% had visited outpatient clinics and 29% had visited the 
emergency room during the last year prior to amputation.
Cumulative incidences of death and reamputation
Figure 4 shows the cumulative incidences of death and 
reamputation for first year after LEA. The HRs for death 
the first year after an AKA (compared with toe amputa-
tion) were 4.41 (95% CI 3.44 to 5.66, p<0.001) with no 
adjustments, 3.39 (95% CI 2.64 to 4.37, p<0.001) after 
adjusting for demographics (gender, age, social status 
and living arrangement) and 4.0 (95% CI 3.09 to 5.19, 
p<0.001) after also adjusting for comorbidities (diabetes, 
arteriosclerosis, hypertension and use of opioids). The 
Table 2 Prevalence of comorbidity among patients with lower extremity amputations in 2010–2011 in Denmark
Major amputations Minor amputations
Total, n (%) Above knee, n (%) Below knee, n (%) Total, n (%)
p Value*n=1782 n=1024 n=758 n=1101
Peripheral vascular disorders 1481 (83) 873 (85) 608 (80) 625 (57) <0.0001
Atherosclerosis† 1428 (80) 844 (82) 584 (77) 589 (54) <0.0001
Hypertension‡ 902 (51) 577 (56) 441 (58) 599 (54) 0.18
Diabetes‡ 697 (39) 331 (32) 366 (48) 710 (64) <0.0001
  Diabetic foot ulcer§ 505 (18) 224 (22) 281 (37) 522(47) <0.0001
  Neuropathy§ 174 (6) 69 (7) 105 (14) 230 (21) <0.0001
  Retinopathy§ 112 (6) 37 (4) 75 (10) 141 (13) <0.0001
  Nephropathy§ 85 (5) 22 (2) 63 (8) 82 (7) 0.0028
Cardiac ischaemia§ 597 (34) 348 (34) 249 (33) 329 (30) 0.04
Cardiac arrhythmia 536 (30) 319 (31) 215 (28) 232 (21) <0.0001
Cerebrovascular disease¶ 540 (30) 317 (31) 223 (29) 195 (18) <0.0001
Congestive heart failure 401 (23) 228 (22) 173 (23) 191 (17) 0.0009
Stroke§ 401 (23) 234 (23) 167 (22) 144 (13) <0.0001
Arthrosis§ 320 (18) 202 (20) 118 (16) 195 (18) 0.86
Chronic pulmonary diseases 356 (20) 227 (22) 129 (17) 129 (12) <0.0001
Fluid and electrolyte disorders 330 (19) 211 (21) 119 (16) 123 (11) <0.0001
Emboli§ 359 (20) 231 (23) 128 (17) 88 (8) <0.0001
Renal failure 252 (14) 129 (13) 123 (16) 133 (12) 0.11
Tumour without metastasis 243 (14) 143 (14) 100 (13) 107 (10) 0.0018
Alcohol addiction 227 (13) 121 (12) 106 (14) 122 (11) 0.18
Obesity 130 (7) 60 (6) 70 (9) 127 (12) 0.0001
Rheumatoid arthritis 139 (8) 77 (8) 62 (8) 90 (8) 0.71
Depression 124 (7) 77 (8) 47 (6) 58 (5) 0.069
Dementia¶ 110 (6) 69 (7) 43 (6) 37 (3) 0.0006
Liver disease 79 (4) 40 (4) 39 (5) 51 (5) 0.80
Metastatic cancer 50 (3) 36 (3) 14 (2) 9 (1) 0.0002
Weight loss 43 (2) 30 (3) 13 (2) 12 (1) 0.0155
Bone cancer§ 24 (1) 14 (1) 10 (1) 2 (−) 0.0013
*p<0.05, major vs minor amputation. Comorbidity, defined according to Elixhauser Comorbidity index.
†Includes only ICD-10- I170;
‡Includes uncomplicated and complicated conditions.
§Not included in the Elixhauser Comorbidity Index.
¶Included from the Charlson Comorbidity Index.
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HRs for death the first year after a BKA (compared with 
foot amputation) were 2.57 (95% CI 1.97 to 3.19, p<0.001) 
without adjustments, 2.28 (95% CI 1.75 to 2.97, p<0.001) 
after adjusting for demographics and 2.39 (95% CI 1.83 
to 3.13, p<0.001) after also adjusting for comorbidity.
The HRs for reamputation the first year after an AKA 
were 4.16 (95% CI 3.24 to 5.34, p<0.001) without adjust-
ments, 3.20 (95% CI 2.49 to 4.13, p<0.001) after adjusting 
for demographics and 3.69 (95% CI 2.85 to 4.79, p<0.001) 
after adjusting for comorbidity. The HRs for reamputa-
tion the first year after a BKA were 2.64 (95% CI 2.02 
to 3.43, p<0.001) without adjustments, 2.34 (95% CI 1.79 
to 3.05, p<0.001) after adjusting for demographics and 
2.4 (95% CI 1.83 to 3.14, p<0.001) after adjusting for 
comorbidity.
DIsCussIOn
This study showed that the prevalence of atheroscle-
rosis was 70% and the prevalence of diabetes was 49% 
in an unselected national cohort of patients undergoing 
LEAs. Among patients with atherosclerosis, 42% had 
not received cholesterol-lowering treatments, although 
87% of these patients had visited their GP within the last 
year preceding the amputation. Additionally, 16% of the 
patients with diabetes were diagnosed with diabetes the 
year of the amputation. The majority of patients (85%–
97%) had contact to their GP within the 14 years prior 
to amputation, and 64% were in contact with a hospital 
outpatient clinic within the 3 years prior to amputation. 
Moreover, 88% of patients undergoing major extremity 
amputation had no previous amputation on a lower level. 
Additionally, only 6% of patients in this cohort had under-
gone revascularisation prior to amputation. Nevertheless, 
one out of three patients received prescribed opioids 
3 years prior to amputation. Traditionally, LEA has been 
associated with long-term complications of diabetes. 
However, the prevalence of CVDs is increasing in Western 
countries; consequently, the traditional perceptions 
must be redefined to identify risk factors for LEA. In our 
national cohort of patients with major amputations, the 
majority (83%) were diagnosed with atherosclerosis, and 
less (33%) had diabetes. In comparison, patients with 
minor amputations had a higher prevalence of diabetes 
(64%) and lower prevalence of atherosclerosis (53%). 
Similar distributions were identified by The Global Lower 
Extremity Amputation Study Group (2000).16
According to the guidelines, our results indicate a 
suboptimal treatment of atherosclerosis and identifica-
tion of diabetes. There was a 28 per cent point differ-
ence between the proportion of patients who received 
cholesterol-lowering drugs and the proportion of 
patients diagnosed with atherosclerosis. Also, among 
patients with diabetes, there was a 6 per cent point gap 
between patients having diabetes and patients receiving 
antidiabetic treatment, indicating an unsolved clinical 
problem in identifying atherosclerosis and diabetes. 
Indeed, timely treatment might have saved these patients 
from an extremity amputation. The lack of recogni-
tion of symptoms related to PAD among both patients 
and healthcare professionals may be linked to a lack of 
knowledge inhibiting patients to react on symptoms and 
consult their GP in time.34 Additionally, only 6% of the 
Table 3 Prevalence of prescribed medications used by patients with lower extremity amputations in 2010–2011 in Denmark
Major amputations Minor amputations
Total, n (%) Above knee, n (%) Below knee, n (%) Total, n (%)
p Value*n=1782 n=1024 n=758 n=1101
Opioids 1484 (83) 876 (86) 608 (80) 684 (62) <0.0001
Antithrombotic drugs 1262 (71) 738 (72) 524 (69) 711 (65) 0.0005
Acetaminophen 1333 (75) 802 (78) 531 (70) 621 (56) <0.0001
Antihypertensives 1000 (56) 577 (56) 423 (56) 715 (65) <0.0001
Cholesterol-lowering drugs 886 (50) 481 (47) 405 (53) 627 (57) 0.0002
Neuropathic pain relievers 919 (52) 517 (50) 402 (53) 330 (30) <0.0001
Antidepressants 864 (48) 501 (49) 363 (48) 365 (33) <0.0001
Antidiabetic therapy 588 (33) 268 (26) 320 (42) 638 (58) <0.0001
Beta blockers 760 (43) 440 (43) 320 (42) 439 (40) 0.14
NSAID 451 (25) 264 (26) 187 (25) 312 (28) 0.07
Drugs for airway disease 337 (19) 199 (19) 138 (18) 146 (14) <0.0001
Alcohol addiction 341 (19) 198 (20) 143 (19) 122 (11) <0.0001
Smoking cessation 259 (15) 155 (15) 104 (14) 132 (12) 0.053
Cortisol 246 (14) 156 (15) 90 (12) 120 (11) 0.023
*p<0.05, major vs minor amputation.
NSAID, non-steroidal anti-inflammatory drug.
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patients had received revascularisations (angioplasty or 
bypass) prior to the index amputation. These results were 
concerning as revascularisation surgery still is an essen-
tial part of the treatment for critical ischaemia in lower 
extremities.35 36 Similarly, Moxey et al also found a low 
prevalence of revascularisation of 9% in an unselected, 
nationwide cohort.37 However, Ahmad et al found a 30% 
prevalence of revascularisation in an unselected popula-
tion cohort in England.11 Ahmad et al also demonstrated 
demographic variations in the prevalence of amputations 
Table 4 Characteristics and comorbidities among patients with lower extremity amputation diagnosed with cardiovascular 
diseases, diabetes or without in 2010–2011
In risk of lower limb amputation No CVD or diabetes
p Value*n=2636
Cardiovascular disease Diabetes
n=247(%)n=1185(%) n=1451(%)
Characteristics
  Male 1680 (64) 637 (54) 1043 (72) 131 (53) <0.0001
  Married 1058 (40) 430 (36) 628 (43) 107 (43) 0.0003
  working 197 (7) 46 (4) 151 (10) 60 (24) <0.0001†
  Retired 1943 (74) 985 (83) 958 (66) 112 (45)
  Social welfare 496 (19) 154 (13) 342 (24) 75 (30)
  Living in rural areas 1548 (59) 704 (59) 844 (58) 157 (64) 0.5
Charlson Index
  0–1 376 (14) 322 (27) 54 (4) 170 (69) <0.0001‡
  2 411 (16) 314 (27) 97 (7) 45 (18)
  3 1849 (70) 549 (46) 1300 (90) 32 (13)
  Previous amputation 252 (10) 55 (5) 197 (14) 14 (6) <0.0001
Multi-morbidities
  Comorbidities, median (IQR) 8 (6; 10) 6 (5; 8) 10 (7; 12) 1 (0; 2) <0.0001
  Drugs, median (IQR) 7 (5; 9) 6 (4; 8) 8 (6; 10) 3 (2; 5) <0.0001
  Ulcer 1360 (52) 489 (41) 871 (60) 80 (32) <0.0001
  Hypertension 1397 (53) 519 (44) 878 (61) 34 (14) <0.0001
  Arthrosis 454 (17) 227 (19) 227 (16) 61 (25) 0.02
  Chronic pulmonary diseases 466 (18) 250 (21) 216 (15) 19 (8) <0.0001
  Tumour without metastasis 310 (12) 178 (15) 132 (9) 40 (16) <0.0001
  Alcohol addiction 319 (12) 156 (13) 163 (11) 30 (12) 0.1
  Obesity 252 (10) 28 (2) 224 (15) 5 (2) <0.0001
  Rheumatoid arthritis 203 (8) 110 (9) 93 (6) 26 (11) 0.006
  Liver disease 109 (4) 41 (3) 68 (5) 21 (9) 0.1
  Metastatic cancer 52 (2) 40 (3) 12 (1) 7 (3) <0.0001
Prescribed medication
  Opioids 2027 (77) 93 (84) 1034 (71) 141 (57) <0.0001
  Cholesterol-lowering drugs 1483 (56) 543 (46) 940 (65) 30 (12) <0.0001
  Antithrombotic drugs 1919 (73) 855 (72) 1064 (73) 54 (22) 0.5
  Antihypertensive 1647 (62) 611 (52) 1036 (71) 68 (28) <0.0001
  Neuropathic pain relievers 1162 (44) 580 (49) 582 (40) 87 (35) <0.0001
  Beta blockers 1161 (44) 475 (40) 686 (47) 38 (15) 0.0002
  Alcohol addiction 420 (16) 226 (19) 194 (13) 43 (17) <0.0001
  Drugs for airway disease 459 (17) 240 (20) 219 (15) 24 (10) 0.0005
*p<0.05, cardiovascular disease vs diabetes.
†p Value represents the distribution of working, retired and social welfare between patients with CVD, diabetes or without.
‡p Value represents the distribution of Charlson Index between patients with CVD, diabetes or without.
Cardiovascular disease includes atherosclerosis, peripheral vascular disorders, cardiac ischaemia, emboli, stroke, cerebrovascular disease. 
Diabetes includes antidiabetic therapy.
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and revascularisations, which were associated with social 
inequalities and the presence of chronic diseases.
The results of this study point towards several possi-
bilities for preventing LEA. The finding that 29% of 
the patients received intensive pain treatment already 
3 years prior to major amputation indicates symptoms 
of critical extremity ischaemia. For comparison, 2.6% of 
the Danish population collected prescribed opioids in 
2011.38 Thus, it is essential that distal lower extremity pain 
should be recognised as a symptom of PAD to ensure that 
patients are referred to specialists to confirm the diag-
nosis.39 40 In Denmark, ankle and toe blood pressures are 
measured to calculate the Ankle-Brachial Index (ABI),41 
a non-invasive diagnostic test for PAD.42 This procedure 
is mainly performed at the hospitals and rarely by the 
GP. Throughout the 14 years preceding amputation, 
Figure 2 Prevalence of comorbidities and prescribed medications during the 14 years preceding major and minor lower 
extremity amputations.
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Figure 3 Fourteen years of estimated progression of chronic diseases and contacts to healthcare system preceding (a, c) 
major and (b, d) minor lower extremity amputations. The prevalence of comorbidities, defined by both ICD-10 coding and the 
use of prescribed medications (ACT code), was estimated each year. GP, general practitioner.
Figure 4 One-year cumulative outcomes. The cumulative probabilities of (left) reamputation procedures and (right) survival are 
shown for patients who received major (above-the-knee amputation (AKA) and below-the-knee amputation (BKA)) and minor 
lower extremity amputations.
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the majority of patients in this study had regular and 
increasing contact with their GPs (prevalence increase 
from 85% to 97%). Thus, early identification might be 
feasible because patients do seek medical advice in the 
years prior to amputation. Furthermore, the proportion 
of patients in contact with outpatient clinics or were 
admitted to hospital increased from 25% and 76% and 
from 32% to 49% during the 14 years preceding the 
amputation. Buckley et al followed patients with diabetes 
for 7 years prior to LEA and concluded a need for early 
referral to specialists to reduce the risk of LEA.23 It has 
been suggested that PAD screening could be performed 
with non-invasive methods like the ABI.43 Other studies 
have indicated that routine screening could promote 
preventive treatment and that a screening strategy could 
cost-effectively prevent the progression of PAD and cardio-
vascular events.44 45 Alternatively, Brand46 and Boulton 
et al47 have suggested that a simple clinical examination 
of a patient’s feet could indicate a need to confirm PAD. 
Thus, treatment could be initiated (including specialist 
referrals) to prevent ulcers due to ischaemia and, thus, 
prevent LEA. This study supports the conclusion made by 
Jones et al that calls for education programs to focus on 
prevention and early identification to ensure adequate 
treatment for preventing LEA.5
In this study, the majority of patients (92%) had no 
history of previous amputation preceding the index 
major amputation. Heyer et al reported that 92% of their 
patients had no previous amputation based on data from 
health insurance companies,12 and Buckley et al found 
that 28% of a selected cohort of patients with diabetes had 
a history of amputations.23 The present study confirms 
that the risk of death is highest among patients with 
major amputation. In contrast, neither demographics nor 
comorbidities could explain the high risk of death. Thus, 
other factors must affect the outcome after LEA, such as 
the general health status and the nutritional status of a 
patient. Also, factors related to the perioperative treat-
ment, like a delay to surgery, could have a negative impact 
on the outcome.48 Similar results were reported by Jones 
et al, Hoffstad et al and Wiessman et al, who called for 
more comprehensive, multi-disciplinary efforts.5 7 10
The strength of this study was the use of a national 
cohort based on the national registry, which contained 
information recorded over a period of 14 years before 
the amputation. Furthermore, we could cross-link data 
in various registries at an individual level, which made 
it possible to follow patients over time. The main limita-
tion was the lack of a control group. An age-matched, 
sex-matched and geographically matched control group 
could allow differentiation between disease progres-
sion due to ageing and disease progression that leads to 
amputation. An inherent limitation was that the data did 
not allow for an estimation of patient compliance with 
the prescribed medication. Further, it was not possible 
to access neither the diagnosis recorded by the GP, as 
these data are not included in the national registry, nor 
the indication for the prescribed medication as this has 
just recently been included in the registry. Finally, data on 
examinations such as ABI prior to the amputation would 
have provided a more comprehensive overview of the 
limb-saving procedure.
COnClusIOn
In this study, one-third of patients with LEA were living 
with undiagnosed or untreated atherosclerosis and one 
out of six were living with undiagnosed diabetes despite a 
regular contact with their GPs and outpatient clinics for 
several years prior to the amputation. For the majority of 
patients undergoing major LEAs, the amputation was a 
first-time amputation. Additionally, only a small number 
of patients underwent limb-saving procedures, although 
one in three had received opioid prescriptions several 
years before the amputation. The overall findings of this 
study suggest that the need for opioids, combined with 
the presence of hypertension, diabetes or another CVD, 
could be an indication of PAD, which is highly associated 
with LEA. Further, clinicians are encouraged to initiate 
medical treatment supplemented with a careful inspec-
tion of the patient’s feet as this non-invasive examination 
may detect an early indication of low circulation.
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